Cancer vaccine gets orphan drug status

July 26, 2002

Antigenics Inc. reports the U.S. Food and Drug Administration grantedthe company's personalized cancer vaccine (Oncophage) orphan drug statusfor the treatment of metastatic melanoma. This offers the company potentialmarket exclusivity for seven years from FDA marketing approval.